Home > Investor Relations > Financial Results > Latest Results

Latest Results

October 25, 2016

FY2016 3Q Consolidated Financial Overview

Financial Highlight (IFRS)

Consolidated Statements of Income

(millions of yen, rounded to the nearest one million yen)

Revenues Cost of sales Marketing and distribution Research and development General and administration
361,517 (183,862) (49,883) (60,263) (8,874)
Operating profit Operating profit ratio (%) Profit before taxes Net income Basic Earnings per share (Yen)
58,635 16.2 59,059 43,702 78.89

Consolidated Balance Sheets

(millions of yen, rounded to the nearest one million yen)

Total assets Total non-current assets Total current assets Total non-current liabilities Total current liabilities
769,863 226,974 542,889 (30,956) (107,703)
Capital and reserves attributable to Chugai shareholders Investment on property, plant and equipment (billion yen) Equity ratio attributable to Chugai shareholders (%) Annual dividends per share (yen) Interim dividends per share (yen)
630,445 15.1 81.9 52.00 (Forecast) 26.00

Revenues: 361.5 billion JPY (-6.3, -1.7% YoY)

Domestic sales excl. Tamiflu®: increase due to steady growth of new products and mainstay products (+1.8, +0.7%)
Overseas sales: decrease due to impact of supply price reduction on Actemra® export, etc. (-9.3, -13.1%)
Royalties and other operating income: decrease due to milestone income (-0.5, -3.4%)

Cost of sales / Operating expenses (Core basis)

Cost of sales: the ratio to sales worsened due to HIP revision and impact of supply price reduction on Actemra® export, etc. (+2.4% points, from 50.3% to 52.7%)
Operating expenses: slight decrease as the decrease of marketing and distribution expenses exceeded the increase of research and development expenses (-0.8, -0.7%)


IFRS results:  
operating profit  58.6 billion JPY (-8.5, -12.7%)
net income  43.7 billion JPY (-4.9, -10.1%)
Core results:  
operating profit  59.6 billion JPY (-10.7, -15.2%)
net income  44.3 billion JPY (-6.4, -12.6%)
EPS  79.93 JPY (-11.08, -12.2%)

Jan-Sep 2016 Sales excluding Tamiflu®

Core Operating Income Jan-Sep

*Amounts are rounded to the nearest 0.1 billion yen.
Variance and % are calculated based on amounts shown.

More Information

To view PDF files,
you will need Adobe® Reader® which is available as a free download.